Merck & Company Inc (MRK)vsXencor Inc (XNCR)
MRK
Merck & Company Inc
$109.18
-1.60%
HEALTHCARE · Cap: $274.03B
XNCR
Xencor Inc
$11.93
+2.67%
HEALTHCARE · Cap: $861.36M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 51670% more annual revenue ($65.01B vs $125.58M). MRK leads profitability with a 28.1% profit margin vs -73.2%. MRK earns a higher WallStSmart Score of 59/100 (C).
MRK
Buy59
out of 100
Grade: C
XNCR
Avoid28
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-13.2%
Fair Value
$96.48
Current Price
$109.18
$12.70 premium
Margin of Safety
+70.4%
Fair Value
$41.34
Current Price
$11.93
$29.41 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 32.8%
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Generating 1.8B in free cash flow
Reasonable price relative to book value
Areas to Watch
Weak financial health signals
Expensive relative to growth rate
Earnings declined 19.3%
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -14.1% — below average capital efficiency
Revenue declined 46.5%
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.
Bull Case : XNCR
The strongest argument for XNCR centers on Price/Book.
Bear Case : MRK
The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.
Bear Case : XNCR
The primary concerns for XNCR are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
MRK profiles as a value stock while XNCR is a turnaround play — different risk/reward profiles.
XNCR carries more volatility with a beta of 0.99 — expect wider price swings.
MRK is growing revenue faster at 5.0% — sustainability is the question.
MRK generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (59/100 vs 28/100), backed by strong 28.1% margins. XNCR offers better value entry with a 70.4% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Xencor Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of cytokine and monoclonal antibody therapies designed to treat cancer patients and autoimmune diseases in the United States and internationally. The company is headquartered in Monrovia, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?